Protocol Ledger

NCT06366464 · Phase III · RECRUITING

A Study of Pitolisant in Patients With Prader-Willi Syndrome

Interventional Phase III clinical trial protocol NCT06366464 sponsored by Harmony Biosciences Management in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-28 Enrollment: 134 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06366464
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)134 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06366464
Protocol FieldVerified Registry Value
NCT IdentifierNCT06366464
Consolidated Lead SponsorHarmony Biosciences Management
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment134 participants (ESTIMATED)
Registered Start Date2024-05-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06366464
Hospital Research SiteLocationSite Profile
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI